Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AXSM Axsome Therapeutics, Inc.

休市中 11-13 16:00:00 EST

141.69

-2.68

-1.86%

盘后142.00

+0.31+0.22%

19:58 EST

最高145.29	最低136.63	成交量97.31万
今开143.74	昨收144.37	日振幅6.00%
总市值74.22亿	流通市值62.42亿	总股本5,238万
成交额1.37亿	换手率2.21%	流通股本4,405万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AXSM","market":"US","secType":"STK","nameCN":"Axsome Therapeutics, Inc.","latestPrice":141.69,"timestamp":1794603600000,"preClose":144.37,"halted":0,"volume":973068,"hourTrading":{"tag":"盘后","latestPrice":142,"preClose":141.69,"latestTime":"19:58 EST","volume":90964,"amount":12888862.12,"timestamp":1794617918760,"change":0.31,"changeRate":0.002188,"amplitude":0.002188},"delay":0,"changeRate":-0.018563413451548154,"floatShares":44050974,"shares":52380818,"eps":-3.052761,"marketStatus":"休市中","change":-2.68,"latestTime":"11-13 16:00:00 EST","open":143.74,"high":145.29,"low":136.63,"amount":136555030.70736,"amplitude":0.059985,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.052761,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1447909200000,"exchange":"NASDAQ","adjPreClose":144.37,"preHourTrading":{"tag":"盘前","latestPrice":145.4827,"preClose":144.37,"latestTime":"09:27 EST","volume":309,"amount":44781.93315,"timestamp":1794580070066,"change":1.1127,"changeRate":0.007707,"amplitude":0.015031},"postHourTrading":{"tag":"盘后","latestPrice":142,"preClose":141.69,"latestTime":"19:58 EST","volume":90964,"amount":12888862.12,"timestamp":1794617918760,"change":0.31,"changeRate":0.002188,"amplitude":0.002188},"volumeRatio":0.9403271258057733,"impliedVol":0.6151,"impliedVolPercentile":0.8725},"requestUrl":"/m/hq/s/AXSM","defaultTab":"news","newsList":[{"id":"1156825489","title":"异动解读｜Axsome Therapeutics, Inc.盘中下跌4.16%，市场消化三季度业绩利好后出现回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1156825489","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156825489?lang=zh_cn&edition=full","pubTime":"2026-11-13 22:47","pubTimestamp":1794581225,"startTime":"0","endTime":"0","summary":"11月13日，Axsome Therapeutics, Inc.盘中下跌4.16%，报138.365美元/股，成交额643.75万美元。近期公司股价一度因三季度业绩超预期而走强，但最新交易时段内，前期围绕盈利前景改善的重估交易有所降温。公司此前披露，三季度每股亏损0.25美元，明显好于市场预期的0.56美元至0.63美元；营收2.597亿美元，高于预期的约2.49亿美元，其中Auvelity净产品销售额达2.076亿美元。市场仍关注Auvelity持续放量及公司在2027年实现盈利的可能性，但阿尔茨海默病激越适应症后续放量节奏仍待观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Axsome Therapeutics回调，业绩利好消化后回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170318508","title":"异动解读｜Axsome Therapeutics, Inc.盘中上涨4.28%，市场继续消化三季度超预期业绩与盈利前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1170318508","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170318508?lang=zh_cn&edition=full","pubTime":"2026-11-11 22:59","pubTimestamp":1794409170,"startTime":"0","endTime":"0","summary":"11月11日，Axsome Therapeutics, Inc.盘中上涨4.28%，报150.485美元/股，成交额2409.43万美元。本次异动的核心催化，仍是市场对公司三季度超预期业绩及盈利拐点预期的持续重估。公司三季度每股亏损0.25美元，明显优于市场预期的0.56美元至0.63美元；营收2.597亿美元，高于预期的约2.49亿美元，其中Auvelity净产品销售额2.076亿美元。机构认为，随着Auvelity收入持续增长，公司有望在2027年实现盈利；不过其阿尔茨海默病激越适应症的放量节奏仍有待进一步观察。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Axsome盘中上涨，三季度业绩超预期引重估","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119772585","title":"异动解读｜Axsome Therapeutics, Inc.盘中上涨5.37%，市场继续消化三季度超预期业绩与盈利前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1119772585","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119772585?lang=zh_cn&edition=full","pubTime":"2026-11-10 23:03","pubTimestamp":1794322991,"startTime":"0","endTime":"0","summary":"11月10日，Axsome Therapeutics, Inc.盘中上涨5.37%，报141.16美元/股，成交额2843.21万美元。本次异动的核心催化来自公司此前披露的三季度业绩超预期，且机构认为其有望在2027年实现盈利，市场对Auvelity放量与亏损收窄逻辑继续重估。公司三季度每股亏损0.25美元，优于市场预期的0.56美元至0.63美元；营收2.597亿美元，高于预期的约2.49亿美元，Auvelity净产品销售额达2.076亿美元。机构指出，随着Auvelity收入持续增长，公司盈利拐点正在临近，尽管阿尔茨海默病激越适应症放量节奏仍有待观察。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Axsome业绩超预期，盈利拐点临近","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136350938","title":"异动解读｜Axsome Therapeutics, Inc.盘中下跌5.27%，财报利好后目标价下调与兑现压力并存","url":"https://stock-news.laohu8.com/highlight/detail?id=1136350938","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136350938?lang=zh_cn&edition=full","pubTime":"2026-11-06 03:07","pubTimestamp":1793905633,"startTime":"0","endTime":"0","summary":"11月6日，Axsome Therapeutics, Inc.盘中下跌5.27%，报129.78美元/股，成交额8349.99万美元。消息面上，公司此前披露第三季度业绩好于预期，但加拿大皇家银行在维持跑赢大盘评级的同时，将目标价从295美元下调至273美元，市场对利好兑现后的估值空间重新评估。公司第三季度每股亏损0.25美元，优于市场预期的0.56美元至0.63美元；营收2.597亿美元，高于预期的约2.49亿美元，较上年同期1.71亿美元明显增长。其中Auvelity净产品销售额为2.076亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Axsome财报超预期，目标价遭下调承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138194844","title":"异动解读｜Axsome Therapeutics, Inc.盘中上涨5.42%，业绩超预期后获机构维持跑赢大盘","url":"https://stock-news.laohu8.com/highlight/detail?id=1138194844","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138194844?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:47","pubTimestamp":1793717253,"startTime":"0","endTime":"0","summary":"11月3日，Axsome Therapeutics, Inc.盘中上涨5.42%，报144.12美元/股，成交额2095.59万美元。消息面上，公司此前披露第三季度业绩明显超预期，叠加加拿大皇家银行将目标价由295美元下调至273美元但维持跑赢大盘评级，带动市场重新评估其基本面。公司第三季度每股亏损0.25美元，优于市场预期的0.56美元至0.68美元；营收2.597亿美元，同比增长约52%，亦高于一致预期约2.49亿美元，净亏损收窄至1290万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"业绩超预期，盘中强势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157114120","title":"异动解读｜Axsome Therapeutics, Inc.盘中下跌10.18%，财报超预期后市场交易分化","url":"https://stock-news.laohu8.com/highlight/detail?id=1157114120","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157114120?lang=zh_cn&edition=full","pubTime":"2026-11-02 22:33","pubTimestamp":1793629994,"startTime":"0","endTime":"0","summary":"11月2日，Axsome Therapeutics, Inc.盘中下跌10.18%，报126.535美元/股，成交额1525.17万美元。消息面上，公司披露第三季度业绩，调整后每股亏损0.25美元，明显好于市场预期的0.56美元至0.68美元；季度销售额约2.60亿美元，也高于市场一致预期约2.50亿美元。从经营表现看，公司当季营收同比增长约52%，净亏损收窄至1290万美元，上年同期为4720万美元。市场此前高度关注Auvelity处方扩张对收入增长和亏损改善的拉动，其上一季度净销售额为1.80亿美元，同比增长51.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"业绩超预期仍下跌，市场交易现分化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153098392","title":"异动解读｜Axsome Therapeutics, Inc.盘前上涨7.32%，第三季度业绩显著超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1153098392","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153098392?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:09","pubTimestamp":1793621363,"startTime":"0","endTime":"0","summary":"11月2日，Axsome Therapeutics, Inc.盘前上涨7.32%，报155.0美元/股，成交额24.99万美元。消息面上，公司披露第三季度业绩，调整后每股亏损为0.25美元，明显好于市场预期的亏损0.56美元至0.68美元；季度销售额约2.60亿美元，也高于约2.49亿美元的一致预期。此前市场普遍关注Auvelity处方扩张对收入与亏损收窄的带动作用。二季度该产品净销售额为1.80亿美元，同比增长51.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"业绩超预期，盘前强势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119937285","title":"财报前瞻 | Axsome Therapeutics, Inc.本季度营收预计增54.51%，机构看多Auvelity","url":"https://stock-news.laohu8.com/highlight/detail?id=1119937285","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119937285?lang=zh_cn&edition=full","pubTime":"2026-10-26 09:22","pubTimestamp":1792977766,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.将于2026年11月02日发布最新季度财报，市场关注Auvelity处方扩张带动的营收与亏损收窄节奏。上一季度公司实现营收2.18亿、同比增长45.54%；毛利率93.79%；归属于母公司净亏损5,131.40万、净利率-23.50%；调整后每股收益-0.99、同比下降2.06%。结合已披露的第二季度净销售额1.80亿、同比增长51.00%，叠加新适应症启动后处方结构优化，本季度Auvelity仍是收入和利润弹性的主导变量。多家机构维持或上调公司目标价，核心论据集中在Auvelity商业化拐点与处方扩张的持续性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Axsome Therapeutics, Inc.本季度营收预计增54.51%，机构看多Auvelity","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112855441","title":"异动解读｜Axsome Therapeutics盘中下跌5.46%，德银下调目标价叠加获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1112855441","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112855441?lang=zh_cn&edition=full","pubTime":"2026-09-30 02:03","pubTimestamp":1790704984,"startTime":"0","endTime":"0","summary":"9月30日，Axsome Therapeutics盘中下跌5.46%，报183.31美元/股，成交额1.48亿美元。消息面上，德意志银行将Axsome Therapeutics目标价从280美元下调至267美元，虽维持买入评级，但目标价下修信号或引发市场短期情绪波动。此前Truist曾大幅上调目标价至285美元，瑞穗维持316美元目标价并指出Auvelity在阿尔茨海默病激越适应症的处方数据保持两位数增长。尽管分析师共识目标价仍维持在282.52美元，但公司此前两季度EPS均不及预期，叠加股价前期累积一定涨幅，短期获利回吐压力显现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"德银下调目标价，Axsome股价承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182767493","title":"异动解读｜Axsome Therapeutics盘中上涨6.24%，Auvelity处方量强劲增长提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1182767493","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182767493?lang=zh_cn&edition=full","pubTime":"2026-09-12 00:13","pubTimestamp":1789143207,"startTime":"0","endTime":"0","summary":"9月12日，Axsome Therapeutics盘中上涨6.24%，报224.28美元/股，成交额1.07亿美元。消息面上，RBC此前发布研报指出，Auvelity在阿尔茨海默病激越适应症获批上市后，新处方量与总处方量出现\"统计学上显著的拐点\"，商业化进展达到或超出华尔街预期。RBC估算Q2新处方约6,300张，Q3有望增至约27,600张；总处方量则从Q2约9,200张增至Q3约37,400张。该行预计Auvelity全年收入可达8.04亿美元，上行空间达8.15亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Auvelity处方量强劲增长，Axsome盘中上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111108043","title":"异动解读｜Axsome Therapeutics盘中上涨5.01%，Q2营收同比增46%盘中收复盘前跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111108043","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111108043?lang=zh_cn&edition=full","pubTime":"2026-08-11 02:58","pubTimestamp":1786388339,"startTime":"0","endTime":"0","summary":"8月10日，Axsome Therapeutics盘中上涨5.01%，报223.4美元/股，成交额2.0亿美元。公司此前盘前因Q2财报每股亏损及营收双双不及预期一度大跌逾8%，但开盘后股价快速反弹收复失地。消息面上，公司Q2实现营收2.184亿美元，同比增长46%，核心产品AUVELITY净销售额达1.803亿美元，同比增长51%，显示商业化放量势头强劲。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120099489","title":"异动解读 | Axsome Therapeutics盘前大跌8.34%，Q2财报每股亏损及营收均不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120099489","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120099489?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:38","pubTimestamp":1786361898,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.今日盘前股价大跌8.34%，引发市场关注。消息面上，公司公布的第二季度财务数据显示，GAAP每股亏损为0.99美元，较市场预期低0.10美元；当期营业收入为2.184亿美元，同比增长45.6%，但较市场一致预期少338万美元。然而，销售、研发等多项运营开支同步走高，导致整体亏损表现不及预期，后续市场将密切跟踪核心药物处方量的变化，以判断增长动能能否延续。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933459","title":"Axsome Therapeutics（AXSM）二季度GAAP每股盈亏为0.99美元 营业收入2.184亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933459","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658933459?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:27","pubTimestamp":1786361253,"startTime":"0","endTime":"0","summary":"金吾财讯 | Axsome Therapeutics 公布第二季度财务数据，公司GAAP每股盈亏为0.99美元，较市场预期低0.10美元。当期实现营业收入2.184亿美元，同比增幅达到45.6%，但较市场一致预期少338万美元。该企业专注于中枢神经系统领域药物开发与商业化，本季度营收大幅上涨，主要来源于已上市药物的市场销售放量。不过销售、研发等多项运营开支同步走高，最终造成每股亏损不及预期。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303617","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UUP","UDN","LENZ","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116287182","title":"Axsome Therapeutics宣布FDA受理Axs-12治疗发作性睡病中猝倒症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1116287182","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116287182?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:02","pubTimestamp":1784113338,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics公司宣布，美国食品药品监督管理局（FDA）已正式受理其新药Axs-12用于治疗发作性睡病中猝倒症的新药申请。这一进展标志着该药物向上市迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","AXSM","BK4007","PTH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105093932","title":"Axsome Therapeutics启动Solriamfetol治疗儿童注意缺陷多动障碍的Focus-2三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1105093932","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105093932?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:04","pubTimestamp":1783422284,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics已正式启动其候选药物Solriamfetol针对儿童注意缺陷多动障碍的Focus-2三期临床试验。这项研究旨在评估该药物在年轻患者群体中的安全性与有效性，标志着公司在该治疗领域研发进程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","PTH","AXSM","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132235371","title":"Axsome Therapeutics启动Solriamfetol治疗青少年注意力缺陷多动障碍的FOCUS-3三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1132235371","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132235371?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:00","pubTimestamp":1782471654,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics已正式启动其药物Solriamfetol用于治疗青少年注意力缺陷多动障碍的FOCUS-3三期临床研究。该试验旨在评估该疗法在青少年患者群体中的安全性与有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","AXSM","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518277592","title":"Axsome Therapeutics, Inc.盘中异动 急速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277592","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518277592?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:42","pubTimestamp":1741617767,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时42分，Axsome Therapeutics, Inc.股票出现异动，股价大幅跳水5.00%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3487.28%、761.92%、648.51%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.06%、41.36%、40.33%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224248abf31732&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224248abf31732&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","BK4139","LENZ","BK4505","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516579633","title":"Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516579633","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516579633?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:51","pubTimestamp":1741006288,"startTime":"0","endTime":"0","summary":"Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03205148492765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AXSM","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514857535","title":"瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857535","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514857535?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:11","pubTimestamp":1740586273,"startTime":"0","endTime":"0","summary":"瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27001148413683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AXSM","161121","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132091385","title":"异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1132091385","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132091385?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:04","pubTimestamp":1740510275,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.(AXSM)今日盘中大跌5.03%,引发了市场广泛关注。\n\nAXSM是一家致力于开发治疗中枢神经系统疾病的新疗法的生物制药公司。从最新财报数据看,公司营收3.86亿美元,净利润则达-2.87亿美元,每股亏损5.99美元。较高的亏损可能是导致股价下跌的主要原因之一。\n\n同时,分析师普遍认为,该公司股价目前市盈率过高,约为-20.76倍,短期内增长动能不足,估值面临压力。机构方面给予100%买入评级,但显然并没能阻止股价下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.axsome.com","stockEarnings":[{"period":"1week","weight":0.0704},{"period":"1month","weight":-0.1266},{"period":"3month","weight":-0.3369},{"period":"6month","weight":-0.3778},{"period":"1year","weight":0.0312},{"period":"ytd","weight":-0.2242}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Axsome Therapeutics, Inc.成立于2012年1月。该公司是一家临床阶段的生物制药企业，开发新的治疗疼痛和其他中枢神经系统或中枢神经系统，疾病管理。通过专注于这一治疗领域，他们正在解决显著和不断增长的市场，其中目前的治疗选择是有限或不充分的。他们的目标是成为一个完全集成的生物制药公司开发和商业化的拓展提供给医护人员的治疗方案，提高生活疼痛和其他中枢神经系统疾病患者的生命分化疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.074403},{"month":2,"riseRate":0.181818,"avgChangeRate":-0.03699},{"month":3,"riseRate":0.363636,"avgChangeRate":0.055503},{"month":4,"riseRate":0.727273,"avgChangeRate":0.158416},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.036488},{"month":6,"riseRate":0.636364,"avgChangeRate":0.116789},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.037279},{"month":8,"riseRate":0.545455,"avgChangeRate":0.039835},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.02425},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.00866},{"month":11,"riseRate":0.636364,"avgChangeRate":0.138677},{"month":12,"riseRate":0.727273,"avgChangeRate":0.190318}],"exchange":"NASDAQ","name":"Axsome Therapeutics, Inc.","nameEN":"Axsome Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Axsome Therapeutics, Inc.(AXSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Axsome Therapeutics, Inc.,AXSM,Axsome Therapeutics, Inc.股票,Axsome Therapeutics, Inc.股票老虎,Axsome Therapeutics, Inc.股票老虎国际,Axsome Therapeutics, Inc.行情,Axsome Therapeutics, Inc.股票行情,Axsome Therapeutics, Inc.股价,Axsome Therapeutics, Inc.股市,Axsome Therapeutics, Inc.股票价格,Axsome Therapeutics, Inc.股票交易,Axsome Therapeutics, Inc.股票购买,Axsome Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Axsome Therapeutics, Inc.(AXSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}